article thumbnail

STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals

STAT

In reality, the arrangements actually resemble private-label distribution, but the lawmakers worry these agreements could cause consumers to pay higher prices. These new business units have since used these deals as springboards to market the medications to health plans.

Labelling 308
article thumbnail

STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT

regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment. Novo said it has also filed for a label expansion in Europe and a decision is expected this year.

Labelling 356
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

STAT

But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.  WASHINGTON — There are three FDA-approved drugs for treating alcohol use disorder.

Labelling 346
article thumbnail

Skinny-Label Lives to See Another Day

FDA Law Blog: Biosimilars

Koblitz — Further talks of the Skinny Label’s demise may be premature, as demonstrated by a new decision from the District Court for the District of Columbia upholding FDA’s interpretation of the “same labeling” provisions of the Hatch-Waxman Amendments. Teva and Amarin v. Citing to “[b]inding Circuit law” in Bristol-Myers Squibb v.

article thumbnail

STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

STAT

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. of those who received placebo.

Labelling 320
article thumbnail

STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more

STAT

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. As the original brand-name manufacturer, however, Merck continues to have legal responsibility for the labeling, which means that all available versions lack the details.

Labelling 143
article thumbnail

STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

STAT

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy. 

Labelling 304